Analysts Anticipate MaxLinear, Inc. (NYSE:MXL) to Post $0.16 EPS

Share on StockTwits

Brokerages expect MaxLinear, Inc. (NYSE:MXL) to post $0.16 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for MaxLinear’s earnings. MaxLinear posted earnings per share of $0.20 during the same quarter last year, which would suggest a negative year over year growth rate of 20%. The business is expected to announce its next quarterly earnings report on Tuesday, February 4th.

According to Zacks, analysts expect that MaxLinear will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.79 to $0.80. For the next year, analysts forecast that the business will post earnings of $0.85 per share, with EPS estimates ranging from $0.82 to $0.90. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover MaxLinear.

MaxLinear (NYSE:MXL) last announced its quarterly earnings data on Thursday, October 24th. The semiconductor company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.02. The firm had revenue of $80.00 million for the quarter, compared to analysts’ expectations of $80.04 million. MaxLinear had a positive return on equity of 8.02% and a negative net margin of 3.43%. The firm’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same period last year, the business posted $0.19 earnings per share.

A number of brokerages recently weighed in on MXL. Roth Capital set a $21.00 price objective on shares of MaxLinear and gave the company a “hold” rating in a research report on Friday, October 25th. ValuEngine raised MaxLinear from a “buy” rating to a “strong-buy” rating in a report on Friday. Stifel Nicolaus set a $26.00 price target on MaxLinear and gave the stock a “buy” rating in a research report on Friday, October 25th. Zacks Investment Research cut MaxLinear from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Needham & Company LLC raised MaxLinear from a “hold” rating to a “buy” rating in a report on Wednesday, November 27th. Five research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $22.50.

Shares of NYSE:MXL traded down $0.41 on Tuesday, reaching $18.93. 206,765 shares of the company’s stock were exchanged, compared to its average volume of 307,394. The business’s 50-day moving average is $20.46 and its two-hundred day moving average is $21.73. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.54. MaxLinear has a fifty-two week low of $15.93 and a fifty-two week high of $28.70. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 24.27, a PEG ratio of 4.36 and a beta of 1.24.

In other news, CEO Kishore Seendripu sold 10,500 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $22.46, for a total transaction of $235,830.00. Following the transaction, the chief executive officer now directly owns 20,677 shares of the company’s stock, valued at $464,405.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Connie H. Kwong sold 2,500 shares of MaxLinear stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $20.75, for a total transaction of $51,875.00. Following the sale, the insider now owns 12,573 shares in the company, valued at $260,889.75. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 45,175 shares of company stock worth $998,488 and sold 64,735 shares worth $1,357,468. Company insiders own 9.97% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of MaxLinear by 11.4% in the second quarter. BlackRock Inc. now owns 10,233,194 shares of the semiconductor company’s stock worth $239,866,000 after buying an additional 1,049,438 shares during the period. Nuveen Asset Management LLC acquired a new stake in shares of MaxLinear in the second quarter worth $6,586,000. Morgan Stanley grew its holdings in shares of MaxLinear by 1,909.7% during the second quarter. Morgan Stanley now owns 285,052 shares of the semiconductor company’s stock valued at $6,681,000 after buying an additional 270,868 shares in the last quarter. Systematic Financial Management LP purchased a new position in shares of MaxLinear during the third quarter valued at $2,720,000. Finally, Chicago Equity Partners LLC purchased a new position in shares of MaxLinear during the second quarter valued at $2,782,000. 87.21% of the stock is owned by institutional investors and hedge funds.

MaxLinear Company Profile

MaxLinear, Inc provides radio-frequency (RF), high-performance analog, and mixed-signal communications systems-on-chip solutions (SoCs) for the connected home, wired and wireless infrastructure, and industrial and multi-market applications worldwide. The company offers range of semiconductor products, such as RF receivers and RF receiver SoCs, wireless infrastructure backhaul RF receivers and modem SoCs, laser modulator drivers, transimpedance amplifiers, clock and data recovery circuits, interface solutions, power management products, and data encryption and compression products.

Recommended Story: Correction

Get a free copy of the Zacks research report on MaxLinear (MXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MaxLinear (NYSE:MXL)

Receive News & Ratings for MaxLinear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxLinear and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.